Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison, Peter Ruane, B. Freilich, Guy Neff, Rashmee Patil, Cynthia Behling, Chen Hu, Erica Fong, Brittany de Temple, Erik J. Tillman, Tim Rolph, Andrew Cheng, Kitty Yale
Topics & Concepts
PlaceboSteatohepatitisMedicineInternal medicineClinical endpointGastroenterologyConfidence intervalAdverse effectRandomized controlled trialFatty liverPathologyDiseaseAlternative medicineFibroblast Growth Factor ResearchLiver Disease Diagnosis and TreatmentKruppel-like factors research